Compare AGCO Corporation (AGCO) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs BridgeBio Pharma Inc — how do they compare? AGCO Corporation trades at $102.25 (market cap $7.06B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 2.4× AGCO Corporation's market cap, and AGCO Corporation pays a 1.19% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AGCO | BBIO | |
|---|---|---|
Market Cap | $7.06B | $16.61B |
Sector | Industrials | Health |
52-Week High | $140.49 | $90.17 |
52-Week Low | $100.14 | $47.29 |
Enterprise Value | $9.33B | $18.16B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $102.83, up 1.18% on the day, but faces bearish technical signals with the stock trading near key support at $102. The agricultural equipment manufacturer reported mixed Q2 2026 results, missing earnings estimates but maintaining a solid balance sheet with $612 million in cash. Recent leadership changes and multiple securities investigations create uncertainty, though the company's valuation remains attractive with a P/E of 14.22 and P/S of 0.73.
While AGCO's fundamentals show resilience with positive cash flow and reasonable valuation, near-term headwinds from weaker industry conditions and legal scrutiny present significant risks. The 37.9% analyst buy rating and $124.63 price target suggest potential upside, but investors should weigh the bearish technical outlook against the company's long-term positioning in precision agriculture.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
